(June 2005)
All compounded formulations are prepared by Olympia Pharmaceuticals under cGMP guidelines and with oversight by national and state pharmacy boards
doi: 10.1016/j.jare.2024.11.036 219 JinCTanKYaoZLinBHZhangDPChenWKet al

2.2 Indications The currently approved indications for these agents include: Type 2 diabetes mellitus Overweight and obesity Beyond diabetes and obesity, further indications under investigation for GLP1 RAs include: Osteoarthritis Obstructive sleep apnea Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis 2.3 Benefits and Harms of Continuation/Discontinuation in the Perioperative Period: 2.3.1 Benefits: According to the guidelines, the acute use of these drugs may offer benefits based on published data: Improved perioperative glycemic control Lower postoperative insulin requirements Reduced risk of hypoglycemia These benefits may lead to reduced complications associated with hyperglycemia (such as a shorter hospital stay, fewer surgical site infections, less acute kidney injury, fewer acute coronary syndromes, reduced critical care admissions, and shorter durations on a ventilator) Improved cardiovascular outcomes 2.3.2 Harms There is an increased risk of pulmonary aspiration

For the RNA-sequencing experiments, two males and two females per genotype were used
Skin damage, however, is also a problem